Table 4.
Predictors of Any Readmissions After Ramp Test Among Baseline Characteristics
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Age, y | 1.01 (0.99–1.03) | 0.46 | ||
| Sex, male | 1.28 (0.76–2.18) | 0.36 | ||
| Race, white | 1.24 (0.90–1.70) | 0.20 | ||
| Body mass index | 0.98 (0.94–1.01) | 0.23 | ||
| Preramp LVAD duration, d | 1.00 (1.00–1.00) | 0.34 | ||
| Nonischemic cardiomyopathy | 0.88 (0.52–1.48) | 0.62 | ||
| Destination therapy | 1.21 (0.65–2.24) | 0.56 | ||
| HeartMate II device | 1.21 (0.70–2.10) | 0.49 | ||
| Hypertension | 0.78 (0.46–1.31) | 0.35 | ||
| Diabetes mellitus | 1.32 (0.78–2.23) | 0.30 | ||
| History of stroke | 0.80 (0.38–1.70) | 0.57 | ||
| Atrial fibrillation | 0.96 (0.56–1.64) | 0.87 | ||
| History of ventricular tachyarrhythmias | 1.08 (0.57–2.04) | 0.81 | ||
| Optimized hemodynamics | 0.46 (0.28–0.78) | 0.004* | 0.40 (0.23–0.67) | 0.001* |
| Hemoglobin, g/dL | 0.80 (0.67–0.95) | 0.010* | 0.77 (0.65–0.91) | 0.002* |
| Hematocrit, % | 0.93 (0.87–0.99) | 0.018* | ||
| eGFR, mL/(min·1.73m2) | 1.0 (0.99–1.01) | 0.85 | ||
| Serum total bilirubin, mg/dL | 1.18 (0.88–1.59) | 0.27 | ||
| Preramp total admission, events/y | 1.10 (0.95–1.27) | 0.21 | ||
| Preramp HF admission, events/y | 0.86 (0.48–1.54) | 0.61 | ||
| Preramp non-HF admission, events/y | 1.13 (0.97–1.31) | 0.12 | ||
eGFR indicates estimated glomerular filtration ratio; HF, heart failure; HR, hazard ratio; LVAD, left ventricular assist device.
*
P<0.05 by Cox proportional hazard ratio regression analyses.